A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women

Trial Profile

A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs MK 6913 (Primary) ; Estradiol
  • Indications Hot flashes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Apr 2016 The protocol has been amended with the addition of safety primary endpoint and hence the trial focus changed to TU and AR
    • 28 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 08 Oct 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top